Elucidating the PL-TrxR1 interaction may shed light on how this alkaloid acts in vivo, and understanding this novel targeting mechanism could lead to the development of small molecule inhibitors of TrxR1 as potential HCC chemotherapeutic agents. Here, TXNRD1 is linked to hepatocellular carcinoma.